Analytical Data
-
Gene name
Siglec-2/CD22
- Application
-
Alternative Names
B-lymphocyte cell adhesion molecule (BL-CAM) (Sialic acid-binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD22)
-
Species
Human
-
Source
HEK293
-
Tag
C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20273
-
Expression Region
20-687aa
-
Molecular Weight
77.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-2, also known as CD22, is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) family, predominantly expressed on B cells. It plays a crucial role in modulating B cell activation, tolerance, and survival. Abnormalities in CD22 expression or function have been implicated in various autoimmune diseases and B cell malignancies. Research on Siglec-2/CD22 recombinant proteins has gained interest due to their potential as therapeutic targets in treating such conditions. These recombinant proteins can be used to explore the structure-function relationship of CD22, investigate its role in immune responses, and develop novel approaches for cancer immunotherapy. By engineering CD22 recombinant proteins, researchers aim to elucidate the mechanisms underlying CD22-mediated signaling and to identify ways to enhance or inhibit its activity, ultimately paving the way for targeted therapies in oncology and autoimmunity. The development of CD22-targeted agents, such as monoclonal antibodies or fusion proteins, has shown promise in clinical settings, offering new avenues for enhancing B cell-targeted treatments and improving patient outcomes.
